Dupixent Asthma denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for dupixent asthma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Step Therapy Before Dupixent for Asthma — and How to Challenge It

Aetna step-therapy ("fail-first") denials for dupilumab (Dupixent) in asthma occur when the plan requires documented failure of one or more specified controller therapies before it will authorize a biologic. If your authorization was denied because Aetna's records do not reflect those prior steps, or because your physician proceeded directly to dupilumab based on your clinical profile, this is the pathway you are navigating.

### Why This Denial Is Appealable

Step-therapy requirements must yield to individual clinical circumstances. Under ERISA §503 and ACA §2719, your plan must evaluate whether the required prior steps are clinically appropriate for your specific case — they are not automatically applicable if a prior therapy is contraindicated, already been tried and failed, or clinically inappropriate given your phenotype. Many states also have step-therapy override statutes that require expedited override when a clinician certifies a required step is harmful or clinically inappropriate. Check whether your state's law applies to your plan type.

### Your Appeal Timeline

• Internal appeal: File within the deadline on your denial notice (commonly 180 days for ERISA plans). Standard decisions within 30–60 days; expedited within 72 hours for urgent situations.
• External review: After internal denial, approximately four months to request independent external review. Expedited external review available for urgent cases.

### Documentation to Gather

1. Diagnosis and phenotype confirmation — pulmonary function tests, specialist notes, and laboratory records confirming the asthma diagnosis, severity, and inflammatory phenotype relevant to the FDA-approved indication for dupilumab. 2. Prior controller therapy history with dates and outcomes — for each step-therapy requirement in Aetna's policy, document: the therapy name, the dates of use, the dose or intensity, the duration, and the specific reason it was inadequate (insufficient response, adverse effect, or clinical contraindication per your physician). 3. Clinical severity documentation — exacerbation frequency and severity, emergency or hospital visits, oral corticosteroid burden, and validated symptom scores. 4. Prescriber medical-necessity letter — your allergist or pulmonologist should address each step-therapy requirement in Aetna's policy directly: confirming failure or explaining why any un-tried step is clinically inappropriate for your case, citing the FDA-approved indication for dupilumab and the applicable professional society guideline organization (e.g., GINA or NAEPP framework). 5. State step-therapy override letter (if applicable) — if your state has a step-therapy override law, your physician should submit the required certification form simultaneously with the appeal.

### Criteria-Mapping Structure

Obtain the exact text of Aetna's step-therapy criteria for dupilumab in asthma from the denial notice or by request. Build a point-by-point response:

| Step-Therapy Requirement | Your Evidence | |---|---| | Required controller therapy #1 (per policy) | [Date tried, duration, outcome or reason inappropriate] | | Required controller therapy #2 (per policy) | [Date tried, duration, outcome or reason inappropriate] | | Phenotype consistent with FDA indication | [Lab or clinical documentation] | | Clinical severity justifying biologic | [Exacerbation data, steroid burden, scores] |

Attach the FDA-approved prescribing information for dupilumab and Aetna's written clinical policy to your appeal so the reviewer can assess each requirement against your chart evidence side by side.